MedPath
HSA Approval

Meropenem Labatec IV Powder for Injection or Infusion 500mg/vial

SIN14660P

Meropenem Labatec IV Powder for Injection or Infusion 500mg/vial

Meropenem Labatec IV Powder for Injection or Infusion 500mg/vial

November 10, 2014

ALLIANCE PHARM PTE. LTD.

ALLIANCE PHARM PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantALLIANCE PHARM PTE. LTD.
Licence HolderALLIANCE PHARM PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, FOR SOLUTION

INTRAVENOUS

Medical Information

J01DH02

meropenem

Manufacturer Information

ALLIANCE PHARM PTE. LTD.

ACS Dobfar S.p.A

ACS Dobfar S.p.A. (intermediate)

Active Ingredients

Meropenem Trihydrate 570 mg eqv to Meropenem anhydrous

500mg

Meropenem

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Meropenem Labatec IV Powder for Injection or Infusion 500mg/vial - HSA Approval | MedPath